QQQ   309.48 (+1.94%)
AAPL   154.26 (+1.67%)
MSFT   267.45 (+4.16%)
META   191.55 (+2.95%)
GOOGL   107.44 (+4.41%)
AMZN   101.90 (-0.27%)
TSLA   195.95 (+0.61%)
NVDA   221.13 (+4.86%)
NIO   10.88 (-0.46%)
BABA   105.53 (+0.08%)
AMD   85.72 (+2.44%)
T   19.31 (-1.38%)
F   13.41 (+2.05%)
MU   61.96 (+3.30%)
CGC   2.81 (-4.75%)
GE   81.96 (-0.47%)
DIS   111.78 (+1.74%)
AMC   6.11 (-10.15%)
PFE   43.62 (-0.32%)
PYPL   83.22 (+1.08%)
NFLX   361.88 (+0.11%)
QQQ   309.48 (+1.94%)
AAPL   154.26 (+1.67%)
MSFT   267.45 (+4.16%)
META   191.55 (+2.95%)
GOOGL   107.44 (+4.41%)
AMZN   101.90 (-0.27%)
TSLA   195.95 (+0.61%)
NVDA   221.13 (+4.86%)
NIO   10.88 (-0.46%)
BABA   105.53 (+0.08%)
AMD   85.72 (+2.44%)
T   19.31 (-1.38%)
F   13.41 (+2.05%)
MU   61.96 (+3.30%)
CGC   2.81 (-4.75%)
GE   81.96 (-0.47%)
DIS   111.78 (+1.74%)
AMC   6.11 (-10.15%)
PFE   43.62 (-0.32%)
PYPL   83.22 (+1.08%)
NFLX   361.88 (+0.11%)
QQQ   309.48 (+1.94%)
AAPL   154.26 (+1.67%)
MSFT   267.45 (+4.16%)
META   191.55 (+2.95%)
GOOGL   107.44 (+4.41%)
AMZN   101.90 (-0.27%)
TSLA   195.95 (+0.61%)
NVDA   221.13 (+4.86%)
NIO   10.88 (-0.46%)
BABA   105.53 (+0.08%)
AMD   85.72 (+2.44%)
T   19.31 (-1.38%)
F   13.41 (+2.05%)
MU   61.96 (+3.30%)
CGC   2.81 (-4.75%)
GE   81.96 (-0.47%)
DIS   111.78 (+1.74%)
AMC   6.11 (-10.15%)
PFE   43.62 (-0.32%)
PYPL   83.22 (+1.08%)
NFLX   361.88 (+0.11%)
QQQ   309.48 (+1.94%)
AAPL   154.26 (+1.67%)
MSFT   267.45 (+4.16%)
META   191.55 (+2.95%)
GOOGL   107.44 (+4.41%)
AMZN   101.90 (-0.27%)
TSLA   195.95 (+0.61%)
NVDA   221.13 (+4.86%)
NIO   10.88 (-0.46%)
BABA   105.53 (+0.08%)
AMD   85.72 (+2.44%)
T   19.31 (-1.38%)
F   13.41 (+2.05%)
MU   61.96 (+3.30%)
CGC   2.81 (-4.75%)
GE   81.96 (-0.47%)
DIS   111.78 (+1.74%)
AMC   6.11 (-10.15%)
PFE   43.62 (-0.32%)
PYPL   83.22 (+1.08%)
NFLX   361.88 (+0.11%)
NASDAQ:IMTX

Immatics - IMTX Stock Forecast, Price & News

$8.73
+0.03 (+0.34%)
(As of 02/7/2023 04:08 PM ET)
Add
Compare
Today's Range
$8.55
$8.81
50-Day Range
$7.81
$11.36
52-Week Range
$5.75
$13.60
Volume
173,421 shs
Average Volume
229,701 shs
Market Capitalization
$665.49 million
P/E Ratio
13.03
Dividend Yield
N/A
Price Target
$27.00

Immatics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
209.6% Upside
$27.00 Price Target
Short Interest
Bearish
4.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Immatics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.59 to ($1.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

811th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

130th out of 168 stocks

IMTX stock logo

About Immatics (NASDAQ:IMTX) Stock

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Stock News Headlines

Immatics (NASDAQ:IMTX) Sees Large Volume Increase
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
IMTX Immatics N.V.
Immatics NV Ordinary Shares - Stock Chart
See More Headlines
Receive IMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter.

IMTX Company Calendar

Last Earnings
11/17/2022
Today
2/07/2023
Next Earnings (Estimated)
3/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMTX
Fax
N/A
Employees
188
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.00
High Stock Price Forecast
$28.00
Low Stock Price Forecast
$26.00
Forecasted Upside/Downside
+209.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-110,430,000.00
Pretax Margin
22.98%

Debt

Sales & Book Value

Annual Sales
$41.13 million
Book Value
$0.45 per share

Miscellaneous

Free Float
N/A
Market Cap
$665.49 million
Optionable
Not Optionable
Beta
0.49

Key Executives

  • Dr. Harpreet Singh Ph.D. (Age 47)
    CEO, MD, Member of Management Board & Supervisory Director
  • Dr. Hans-Georg Rammensee Ph.D.
    Co-Founder & Member of the Scientific Advisory Board
  • Dr. Toni Weinschenk Ph.D. (Age 49)
    Co-Founder & Chief Innovation Officer
  • Mr. Arnd Christ MBA (Age 56)
    Chief Financial Officer
  • Mr. Steffen Walter Ph.D. (Age 46)
    Chief Technology Officer
  • Mr. Edward A. Sturchio
    Gen. Counsel & Sec.
  • Ms. Anja Heuer B.Sc.
    Director of Corp. Communications
  • Ms. Tamara Louw M.B.A.
    P.H.R., Sr. Director of HR
  • Dr. Carsten Reinhardt M.D. (Age 55)
    Ph.D., Chief Devel. Officer
  • Dr. Rainer Kramer Ph.D. (Age 57)
    Chief Bus. Officer & Site Head Munich













IMTX Stock - Frequently Asked Questions

Should I buy or sell Immatics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares.
View IMTX analyst ratings
or view top-rated stocks.

What is Immatics' stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month price targets for Immatics' shares. Their IMTX share price forecasts range from $26.00 to $28.00. On average, they predict the company's stock price to reach $27.00 in the next year. This suggests a possible upside of 210.3% from the stock's current price.
View analysts price targets for IMTX
or view top-rated stocks among Wall Street analysts.

How have IMTX shares performed in 2023?

Immatics' stock was trading at $8.71 at the start of the year. Since then, IMTX shares have decreased by 0.1% and is now trading at $8.70.
View the best growth stocks for 2023 here
.

When is Immatics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our IMTX earnings forecast
.

How were Immatics' earnings last quarter?

Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Thursday, November, 17th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. The firm had revenue of $15.18 million for the quarter, compared to analysts' expectations of $13.36 million. Immatics had a net margin of 24.60% and a trailing twelve-month return on equity of 40.49%.

What other stocks do shareholders of Immatics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX).

What is Immatics' stock symbol?

Immatics trades on the NASDAQ under the ticker symbol "IMTX."

How do I buy shares of Immatics?

Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immatics' stock price today?

One share of IMTX stock can currently be purchased for approximately $8.70.

How much money does Immatics make?

Immatics (NASDAQ:IMTX) has a market capitalization of $663.20 million and generates $41.13 million in revenue each year. The company earns $-110,430,000.00 in net income (profit) each year or $0.67 on an earnings per share basis.

How many employees does Immatics have?

The company employs 188 workers across the globe.

How can I contact Immatics?

Immatics' mailing address is 51 ASTOR PLACE 10TH FLOOR, NEW YORK NY, 10003. The official website for the company is www.immatics.com. The company can be reached via phone at 49-7071-539-7700.

This page (NASDAQ:IMTX) was last updated on 2/7/2023 by MarketBeat.com Staff